Laurus Labs completes USFDA inspection of API facilities in Visakhapatnam

14 Jun 2019 Evaluate

Laurus Labs has successfully completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature. This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

610.90 6.70 (1.11%)
21-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.90
Dr. Reddys Lab 1199.30
Cipla 1523.30
Lupin 2115.70
Zydus Lifesciences 918.35
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...